These are trivial trial questions. I will be happy to help here.
First, Dermatology dept. of Sheba has about 1300 Inpatients and 40000 Outpatients each year. Do you think Sheba/OWCP need to put an AD out there to "recruit" about 20-30 volunteers in that case? Don't you think the dept. has already access to the contact information of the patients that visits it on a regular basis??
Some trials compensate the volunteers and some don't, like in some experimental trials for new drugs here.
But, don't you think a regular patient that visits the dept. for Psoriasis on a regular basis would LOVE to be among those experimental trials like we have in our country here? Ask Gary...he knows since he has actually participated in some of those experimental trials.
Did you know there is a fierce competition to get to experimental trials for various studies in U.S. because people know those trials are the cutting edge of modern medicine and the only shear of hope for more advanced patients?
Also, it is against the law to discriminate subjects/volunteer recruit based on religious belief, sexual orientation, etc. If it changes later, that would be a different story.
Glad I was able to help.
**************************************
Please, any savvy long investors here can answer a couple of simple questions?
1-How many people with the skin condition are needed to run part 2 of part 1?
2-Where are these patients found and contacted?
3-Are there age groups, sexual orientation, male/ female, nationality
requirements or religious beliefs a deciding factor in enrollment?
4- Are participants compensated and if so, how much?
5- Who is overseeing this trial?
Sheba- Dermatology Unit at a Glance
Number of Patients per Year :
1300 Inpatients, 40000 Outpatients
Number of Beds
15
Specialty Clinics:
Phototherapy,Dermatopathology, Dermato-Oncology, Dermato-Allergology,Dermato-Pharmacoloy, Mycology Laboratorium,Complementary Medicine, and Difficult Case Clinic
Read the rest for one proof of Sheba/OWCP cooperation!
On December 29, 2016, OWC Pharmaceutical Research Corp. (the “Registrant”), through its wholly-owned Israeli subsidiary, One World Cannabis Ltd. (‘OWC”), entered into a Research Agreement with Medical Research Infrastructure Development and Health Services Fund by Chaim Sheba Medical Center, a non-profit organization incorporated under the laws of the State of Israel (the “Fund”), a copy of which Research Agreement is attached as Exhibit 10.21. hereto.
